Company Overview and News
TORONTO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland”) (TSX: NPI) announced it will release its 2018 third quarter financial results after market close on November 6, 2018. Northland's management will hold an investor conference call at 10 a.m. Eastern Time (ET) on Wednesday, November 7, 2018, followed by a question and answer period.
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced the opening of its offshore wind operations hub in Germany. The hub represents an expansion of Northland’s focus on offshore wind operations. Initial activities are focused on achieving synergies across the 332 MW Nordsee One wind farm, which commenced commercial operations in 2017, and the 269 MW Deutsche Bucht project, which is currently in construction.
Sept 11 (Reuters) - Canada’s main stock index touched over three-month lows on Tuesday led by declines in materials companies amid the ongoing Sino-U.S. trade dispute and uncertainty over the future of NAFTA trade pact.
FR OMI IMO ABX OMI ACBFF NPIFF IMO SU NPI OROXF RNX RNX.WT ACB RNKLF CNQ BRPIF FQVLF AG FQM ABX SU
Brookfield Renewable (BEP) (TSX:BEP.UN) posted a weak Q2 2018 result mainly primarily due to weak hydro generation in North America. This weak result does not alter our long-term view of the company. Instead, we believe investors should consider the quality of its business. The company should be able to continue to grow its funds from operations thanks to its inflation-protected power purchase agreements, cost-saving initiatives, and the potential to re-contract its PPAs at higher prices.
TORONTO, July 19, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) announced today that the Deutsche Bucht Mono Bucket pilot demonstrator ("Demo") project has reached financial close. All required funds for the Demo project have been contributed by Northland and committed by the project lenders.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
BAMGF H BRLXF NPIFF BAMKF HRNNF BAM TERP NPI
Innergex Renewable Energy (OTCPK:INGXF) (TSX:INE) is a Canada-based renewable power producer with a focus on hydroelectric, wind power and solar photovoltaic projects. The company is currently trading at a premium valuation to its peers. Its valuation is supported by its growth potential, long weighted-average PPA duration, and low maintenance expenditure. However, its debt load is quite high and rising benchmark bond yield can impact its share price.
RNW INE AXY NPIFF MGMXF INGXF MGMXD TRSWF TTM AQN NPI
TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland”) (TSX:NPI) announced it will release its 2018 second quarter financial results after market close on August 8, 2018. Northland management will hold an investor conference call at 10:00 a.m. Eastern Time (ET) on Thursday, August 9, 2018, followed by a question and answer period.
Not for distribution to U.S. newswire services or for dissemination in the United States or its possessions. Any failure to comply with this restriction may constitute a violation of U.S. securities law.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:NPI / Northland Power Inc. on message board site Silicon Investor.